Levobupivakain Kabi (Levobupivacaine Hydrochloride)

Levobupivacaine blocks voltage‑gated sodium channels on neuronal membranes, preventing the initiation and propagation of action potentials. This inhibition stops nerve impulse transmission, resulting in loss of sensation in the area where the drug is applied.

The dose of Levobupivakain Kabi is determined by the prescribing clinician based on the type of procedure, patient characteristics, and route of administration. Healthcare professionals adjust the amount to achieve the desired anesthetic effect while maintaining safety.

Safety data for levobupivacaine during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Use only if the potential benefit justifies any potential risk to the fetus or infant, and follow local regulatory guidance.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Levobupivakain Kabi contains levobupivacaine, the S‑enantiomer of bupivacaine, offering a similar duration of anesthesia with a lower risk of cardiotoxicity and central nervous system toxicity. Clinicians may prefer it when a safer profile is desired for high‑risk patients.

Store the product at controlled room temperature, below 25 °C, in its original packaging. Protect it from moisture, direct sunlight, and extreme temperatures. Do not freeze. Inspect the solution for particulate matter or discoloration before use.

Levobupivakain Kabi is administered by a qualified healthcare professional via epidural, infiltration, intrathecal, or peripheral injection. The specific technique and volume depend on the clinical indication and patient factors, and it should be performed under appropriate monitoring.

Serious risks include cardiac arrhythmias, seizures, severe hypotension, methemoglobinemia, and allergic reactions such as anaphylaxis. Prompt recognition and supportive management are essential if any of these events occur during or after administration.

Patients with known hypersensitivity to levobupivacaine or other amide‑type local anesthetics, those with severe cardiac conduction disorders, or individuals with uncontrolled epilepsy should avoid this medication. Clinical judgment is required for patients with significant hepatic impairment.